COMPANY

Invirsa

Location: Columbus, OH · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Dry Eye Disease Non-center Involved Diabetic Macular Edema Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy Diabetic Retinopathy Center-involved Diabetic Macular Edema Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy Acute Infectious Keratoconjunctivitis INV-102

4Trials (company is sponsor)

Timeline

Sep 7, 2024 Trial start Phase 2: Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy source ↗
Mar 27, 2024 Trial start Phase 2: Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease source ↗
Jun 9, 2023 Trial start Phase 2: Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis source ↗
Aug 30, 2022 Trial start Phase 1/Phase 2: Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT06599684	Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy	Phase 2	Completed	Sep 7, 2024	Sep 30, 2025 (actual)
NCT05636228	Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis	Phase 2	Completed	Jun 9, 2023	Aug 22, 2024 (actual)
NCT05586152	Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease	Phase 1/Phase 2	Completed	Aug 30, 2022	May 2, 2023 (actual)
NCT06370039	Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease	Phase 2	Completed	Mar 27, 2024	Jul 3, 2024 (actual)